UMSARS Versus Laryngoscopy-Based Assessment of Dysphagia.

UMSARS dysphagia ear nose and throat assessment multiple system atrophy

Journal

Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 29 11 2022
revised: 01 03 2023
accepted: 23 03 2023
medline: 19 6 2023
pubmed: 19 6 2023
entrez: 19 6 2023
Statut: epublish

Résumé

Multiple System Atrophy (MSA) dysphagia is routinely assessed by the Unified Multiple System Atrophy Rating Scale (UMSARS) part I-item 2. To compare the UMSARS part I-item 2 with an ear/nose/throat (ENT) expert physician assessment. We retrospectively analyzed the data of MSA patients who underwent an ENT assessment (nasofibroscopic and radioscopic exam) and an annual UMSARS assessment. Deglutition Handicap Index (DHI) and pulmonary/nutrition complications were collected. Seventy-five MSA patients were included. The ENT assessment revealed more severe dysphagia compared to the UMSARS part I-item 2 score ( The UMSARS-based assessment of dysphagia does not capture key aspects of pharyngo-laryngeal dysfunction reflecting swallowing efficiency.

Sections du résumé

Background UNASSIGNED
Multiple System Atrophy (MSA) dysphagia is routinely assessed by the Unified Multiple System Atrophy Rating Scale (UMSARS) part I-item 2.
Objective UNASSIGNED
To compare the UMSARS part I-item 2 with an ear/nose/throat (ENT) expert physician assessment.
Methods UNASSIGNED
We retrospectively analyzed the data of MSA patients who underwent an ENT assessment (nasofibroscopic and radioscopic exam) and an annual UMSARS assessment. Deglutition Handicap Index (DHI) and pulmonary/nutrition complications were collected.
Results UNASSIGNED
Seventy-five MSA patients were included. The ENT assessment revealed more severe dysphagia compared to the UMSARS part I-item 2 score (
Conclusions UNASSIGNED
The UMSARS-based assessment of dysphagia does not capture key aspects of pharyngo-laryngeal dysfunction reflecting swallowing efficiency.

Identifiants

pubmed: 37332653
doi: 10.1002/mdc3.13734
pii: MDC313734
pmc: PMC10272892
doi:

Types de publication

Journal Article

Langues

eng

Pagination

974-979

Informations de copyright

© 2023 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Références

Ann Otol Rhinol Laryngol. 2003 Jul;112(7):630-6
pubmed: 12903684
Neurology. 2019 Oct 1;93(14):630-639
pubmed: 31570638
Mov Disord. 2004 Dec;19(12):1391-402
pubmed: 15452868
Mov Disord. 2022 Mar;37(3):535-544
pubmed: 34773420
Lancet Neurol. 2013 Mar;12(3):264-74
pubmed: 23391524
Neurobiol Dis. 2020 Jun;139:104813
pubmed: 32087288
Mov Disord. 2020 Dec;35(12):2174-2183
pubmed: 32757231
Nat Rev Dis Primers. 2022 Aug 25;8(1):56
pubmed: 36008429
Parkinsonism Relat Disord. 2019 Jul;64:73-81
pubmed: 30902528
Parkinsonism Relat Disord. 2012 May;18(4):311-5
pubmed: 22137459
Dysphagia. 2022 Feb;37(1):65-73
pubmed: 33515311
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Mov Disord. 2022 Jun;37(6):1131-1148
pubmed: 35445419
Mov Disord. 2022 Dec;37(12):2336-2341
pubmed: 36074648
Neurogastroenterol Motil. 2019 Mar;31(3):e13524
pubmed: 30548367
Parkinsonism Relat Disord. 2021 May;86:124-132
pubmed: 33839029

Auteurs

Nadia El Fassi (N)

Department of ENT Hospital of Larrey Toulouse France.

Anne Pavy le Traon (A)

French Reference Center for Multiple System Atrophy, Neurology Department Toulouse university hospital and Institute of Metabolic and Cardiovascular Diseases INSERM UMR 1297 Toulouse France.

Emmanuelle Mouchon (E)

Department of ENT Hospital of Larrey Toulouse France.

Olivier Rascol (O)

Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse INSERM, University of Toulouse 3, CHU of Toulouse Toulouse France.

Wassilios G Meissner (WG)

CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc Bordeaux France.
Univ. Bordeaux, CNRS, IMN, UMR 5293 Bordeaux France.
Dept. Medicine University of Otago, Christchurch, and New Zealand Brain Research Institute Christchurch New Zealand.

Alexandra Foubert-Saumier (A)

CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc Bordeaux France.
Univ. Bordeaux, CNRS, IMN, UMR 5293 Bordeaux France.

Yohan Gallois (Y)

Department of ENT Hospital of Larrey Toulouse France.

Samuel Tessier (S)

Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, Faculté de Médecine, de Pharmacoépidémiologie et d'Informations Sur Le Médicament CIC INSERM 1436, Centre Hospitalier Universitaire Toulouse France.

Fabienne Ory-Magne (F)

Department of Neurology University Hospital of Toulouse Toulouse France.

Virginie A Woisard (VA)

Department of ENT Hospital of Larrey Toulouse France.

Margherita Fabbri (M)

Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse INSERM, University of Toulouse 3, CHU of Toulouse Toulouse France.

Classifications MeSH